Johnson & Johnson MedTech has announced the one-year results of the DISRUPT BTK II post-market study evaluating the safety and effectiveness of the Shockwave Peripheral Intravascular Lithotripsy (IVL) System for treating calcified lesions below the knee in patients with peripheral artery disease. The findings, which were presented at the Vascular InterVentional Advances (VIVA) 2025 meeting, included outcomes from 250 patients across 38 sites globally, with 80% having chronic limb-threatening ischemia (CLTI). At one year, 94.8% of patients were free from major target limb amputation, and 84.5% were free from clinically driven target revascularization. The results demonstrate the durability and safety profile of IVL in complex below-the-knee anatomies.